Page last updated: 2024-09-05

sdz mrl 953 and Neoplasms

sdz mrl 953 has been researched along with Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Engelhardt, R; Färber, L; Gaboriau, E; Galanos, C; Haus, U; Kiani, A; Knopf, HP; Mertelsmann, R; Otto, F; Seiz, A; Stütz, P; Tschiersch, A	1

Trials

1 trial(s) available for sdz mrl 953 and Neoplasms

Article	Year
Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood, 1997, Aug-15, Volume: 90, Issue:4 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Toxins; Cytokines; Double-Blind Method; Down-Regulation; Endotoxins; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Lipid A; Lipopolysaccharides; Middle Aged; Neoplasms; Neutrophils; Prospective Studies; Salmonella; Tumor Necrosis Factor-alpha	1997

Article

Year

Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients.

Blood, 1997, Aug-15, Volume: 90, Issue:4

Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Toxins; Cytokines; Double-Blind Method; Down-Regulation; Endotoxins; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Lipid A; Lipopolysaccharides; Middle Aged; Neoplasms; Neutrophils; Prospective Studies; Salmonella; Tumor Necrosis Factor-alpha

1997